Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC trimmed its holdings in shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) by 56.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 83,700 shares of the company's stock after selling 106,900 shares during the period. Renaissance Technologies LLC owned about 0.30% of Vistagen Therapeutics worth $247,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. JPMorgan Chase & Co. grew its holdings in shares of Vistagen Therapeutics by 4,826,425.0% during the fourth quarter. JPMorgan Chase & Co. now owns 772,244 shares of the company's stock worth $2,278,000 after buying an additional 772,228 shares in the last quarter. Landscape Capital Management L.L.C. purchased a new position in shares of Vistagen Therapeutics during the fourth quarter valued at approximately $123,000. Prosperity Wealth Management Inc. acquired a new stake in Vistagen Therapeutics during the fourth quarter worth approximately $86,000. Jane Street Group LLC purchased a new stake in Vistagen Therapeutics in the 3rd quarter worth approximately $59,000. Finally, Blair William & Co. IL grew its stake in Vistagen Therapeutics by 11.3% in the 4th quarter. Blair William & Co. IL now owns 98,466 shares of the company's stock worth $290,000 after acquiring an additional 10,000 shares during the period. 78.39% of the stock is owned by hedge funds and other institutional investors.

Vistagen Therapeutics Trading Down 0.4%

Shares of Vistagen Therapeutics stock traded down $0.01 during trading hours on Friday, reaching $2.24. 67,943 shares of the company's stock were exchanged, compared to its average volume of 167,852. Vistagen Therapeutics, Inc. has a 52-week low of $1.90 and a 52-week high of $4.75. The company has a fifty day moving average of $2.40 and a 200-day moving average of $2.67. The firm has a market capitalization of $64.65 million, a price-to-earnings ratio of -1.51 and a beta of 0.67.

Vistagen Therapeutics (NASDAQ:VTGN - Get Free Report) last released its earnings results on Thursday, February 13th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.02. Vistagen Therapeutics had a negative return on equity of 48.12% and a negative net margin of 6,777.08%. The firm had revenue of $230 billion for the quarter, compared to the consensus estimate of $0.18 million. On average, equities research analysts anticipate that Vistagen Therapeutics, Inc. will post -1.77 earnings per share for the current fiscal year.

Vistagen Therapeutics Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.